ERBA Diagnostics Announces Delay in Filing Annual Report on Form 10-K
April 01 2015 - 8:00AM
ERBA Diagnostics, Inc. (NYSE MKT:ERB), a fully integrated in vitro
diagnostics company, announced that it is delaying the filing of
its Annual Report on Form 10-K for the year ended December 31, 2014
with the Securities and Exchange Commission (the "SEC").
As disclosed in the Notification of Late Filing on Form 12b-25,
which ERBA Diagnostics filed with the SEC on April 1, 2015, ERBA
Diagnostics delayed filing its Annual Report on Form 10-K because
of unforeseen delays in connection with completing and filing its
consolidated financial statements and the accompanying
footnotes.
Pursuant to Rule 12b-25 under the Securities Exchange Act of
1934, ERBA Diagnostics received an extension until April 15, 2015
to file its Annual Report on Form 10-K. ERBA Diagnostics is working
diligently to complete and file its Annual Report on Form 10-K with
the SEC, which, as previously disclosed in the Notification of Late
Filing on Form 12b-25, ERBA Diagnostics expects to do on or prior
to April 15, 2015.
About ERBA Diagnostics, Inc.
ERBA Diagnostics, Inc. (NYSE MKT:ERB), is a fully
integrated in vitro diagnostics company, offering a comprehensive
suite of clinical testing products throughout the U.S. and emerging
markets. The Company serves as a one-stop shop for the testing
needs of the growing number of smaller hospitals, reference labs,
and physician clinics. ERBA Diagnostics' line of proprietary
and automated instruments, test kits, and reagents provide
customers with autoimmune, infectious diseases, clinical chemistry,
hematology, and diabetes testing. www.erbadiagnostics.com
Safe Harbor Statement
Except for the historical matters contained herein, statements
in this press release are forward-looking and are made pursuant to
the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. Investors are cautioned that forward-looking
statements involve risks and uncertainties that may affect the
business and prospects of ERBA Diagnostics, including, without
limitation, the risks and uncertainties that: ERBA Diagnostics'
financial results may take longer to prepare than anticipated; ERBA
Diagnostics may not be able to file its Annual Report on Form 10-K
for the year ended December 31, 2014 on or prior to the timeframe
set forth above; and other risks and uncertainties that may cause
results to differ materially from those set forth in the
forward-looking statements. See also the section entitled
"Risk Factors" in our Annual Report on Form 10-K for the year ended
December 31, 2013, filed with the SEC, for further discussion of
certain risks and uncertainties that could materially and adversely
affect our business, operating results or financial
condition. Many of these factors are beyond our control.
CONTACT: Investors & Media
Tom Baker
Stonegate, Inc.
Tel: 617.532.0624
tbaker@stonegateinc.com